Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
Cell & Gene Therapy
Biotech
4DMT lays off 25% of workforce while phase 3 timeline ramps up
4D Molecular Therapeutics laid off a quarter of its workforce last month with early-stage R&D bearing the brunt of the changes.
James Waldron
Jul 3, 2025 4:52am
Oncternal sells cancer assets to mystery biotech, winds down ops
Jul 1, 2025 9:38am
AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market
Jun 30, 2025 9:45am
Minovia skates SPAC-wards into public market
Jun 25, 2025 10:33am
Fierce Pharma
FDA investigates 2 deaths after Sarepta Duchenne gene therapy
Jun 25, 2025 10:26am
Biogen to take Spinraza follow-up into registrational studies
Jun 25, 2025 8:04am
More News
Bayer-owned BlueRock lays off 50 employees, shuts Cambridge labs
Jun 25, 2025 7:46am
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
Vertex diabetes islet cell therapy improves blood sugar levels
Jun 23, 2025 4:21am
Industry disappointed as FDA reportedly puts Verdun on leave
Jun 20, 2025 1:53am
See more stories
